GlassScriptPhysician profile
Lester B Collins
NPI 1750305710
$4,732.99
in general payments reported to CMS, 2019-2025
33 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $51.04 · 2021: $44.65 · 2022: $185 · 2023: $1,677 · 2024: $691 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Travel and Lodging: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.86 |
| Travel and Lodging | $744.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,475.45 | 2023-2025 | Infinity, Proclaim |
| Amgen INC. | $519.63 | 2019-2025 | Uplizna |
| Livanova USA, INC. | $444.56 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurocrine Biosciences, INC. | $403.01 | 2019-2025 | Ingrezza |
| Biogen, INC. | $241.18 | 2019-2024 | Tysabri, Vumerity |
| Mdd US Operations, LLC | $206.49 | 2024-2025 | Gocovri |
| Abbvie INC. | $170.82 | 2023-2025 | Duopa |
| Biotronik INC. | $124.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $121.35 | 2019-2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $116.61 | 2019 | |
| Jazz Pharmaceuticals INC. | $109.09 | 2019 | |
| Genentech USA, INC. | $103.39 | 2019-2022 | |
| Grifols USA, LLC | $70.36 | 2024 | Gamunex-C |
| Ucb, INC. | $59.81 | 2019 | |
| Kyowa Kirin, INC. | $59.07 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $58.28 | 2019 | |
| Lilly USA, LLC | $48.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.21 | 2019 | |
| Harmony Biosciences LLC | $45.10 | 2022 | |
| Genzyme Corporation | $44.62 | 2019 | |
| Csl Behring | $34.07 | 2019 | |
| Emd Serono, INC. | $32.76 | 2019 | |
| Avanir Pharmaceuticals, INC. | $27.38 | 2019 | |
| Philips North America LLC | $26.32 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.61 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.10 | 2022 | |
| Horizon Therapeutics Plc | $17.85 | 2023 | Uplizna |
| Haemonetics Corporation | $17.72 | 2025 | Teg6s Hemostasis System |
| Bayer Healthcare Pharmaceuticals INC. | $16.02 | 2019 | |
| Acadia Pharmaceuticals INC | $15.57 | 2019 | |
| Pfizer INC. | $14.36 | 2023 | |
| Allergan, INC. | $11.80 | 2019 | |
| Lundbeck LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.